Back to results
US 2026/0226116 A1Published application
Treatment of fragile x syndrome
AssigneeUTI Limited Partnership
InventorsRaymond W. TURNER, Xiaogin ZHAN, Hadhimulya ASMARA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to the treatment of Fragile X Syndrome.
Claims66
A recombinant fusion polypeptide, comprising:
- a FMRP(444-632) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.
A recombinant fusion polypeptide, comprising:
- a FMRP(399-570) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.
A recombinant fusion polypeptide, comprising:
- a FMRP(205-399) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.
Dependencies are inferred from the claim text.